Roche to Present New data of Hemlibra (emicizumab) in P-IIIb STASEY Study for Hemophilia A at ISTH 2021
Shots:
- The company will present data from the final analysis of P-IIIb STASEY study of Hemlibra (emicizumab) reinforcing the safety & efficacy of Hemlibra in people with hemophilia A with factor VIII inhibitors
- Spark will share data from the P-I/II study of SPK-8011- demonstrating that hepatocyte expression of factor VIII can be stable and durable up to 4yrs. following vector administration- with an acceptable safety profile. The results showed 93% reduction in ABR and a 97% reduction in annualized infusion rate
- Additionally- the company will present the data from the 2017 CHESS PAEDs study that demonstrated the treatment needs & clinical burden in children with hemophilia A
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com